This announcement is a separate document:
精優藥業：主要及關連交易 - 建議修訂領航醫藥及生物科技有限公司所發行於二零二一年到期之715,000,000港元可換股債券之條款及條件
EXTRAWELL PHAR: MAJOR AND CONNECTED TRANSACTION - PROPOSED AMENDMENTS TO THE TERMS AND CONDITIONS OF HK$715,000,000 CONVERTIBLE BONDS DUE 2021 ISSUED BY INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.